Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Abbara, Ali; Ufer, Mike; Voors-Pette, Christine; Berman, Lance; Ezzati, Max; Wu, Rui; Lee, Tien-Yi; Ferreira, Juan Camilo Arjona; Migoya, Elizabeth; Dhillo, Waljit S.

doi:10.1016/j.fertnstert.2023.10.031

Fertility and Sterility

2024

DOI: 10.1016/j.fertnstert.2023.10.031

|View full text |Cite

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Ali Abbara,

Mike Ufer,

Christine Voors-Pette

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome

Chen,

Wang,

Chen

et al. 2024

Endocrine Reviews

View full text Add to dashboard Cite

The treatment of polycystic ovary syndrome (PCOS) faces challenges as all known treatments are merely symptomatic. The U.S. Food and Drug Administration (FDA) has not approved any drug specifically for treating PCOS. As the significance of genetics and epigenetics rises in drug development, their pivotal insights have greatly enhanced the efficacy and success of drug target discovery and validation, offering promise for guiding the advancement of PCOS treatments. In this context, we outline the genetic and epigenetic advancement in PCOS, which provide novel insights into the pathogenesis of this complex disease. We also delve into the prospective method for harnessing genetic and epigenetic strategies to identify potential drug targets and ensure target safety. Additionally, we shed light on the preliminary evidence and distinctive challenges associated with gene and epigenetic therapies in the context of PCOS.

show abstract

Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome

Chen,

Wang,

Chen

et al. 2024

Endocrine Reviews

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Cited by 1 publication

References 37 publications

Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome

Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome

Contact Info

Product

Resources

About